• ქართული
  • English
  • Sanofi eyes more EPS growth this year as it narrows focus

    Sanofi said on Thursday its earnings per share were likely to rise by around 5% in 2020, weeks after it promised to focus on vaccines and key treatments including eczema medicine Dupixent until 2022.

    Market Quotes by TradingView